

## Clean Air Systems for Operating Theatres.



7.48 Uhr: Keimzahl 15, 22 C, 55% r. F.

8.20 Uhr: Keimzahl 15, 22 C, 55% r. F.

8.45 Uhr: Keimzahl 15, 22 C, 55% r. F.



9.05 Uhr: Keimzahl 15, 22 C, 55% r. F.



9.38 Uhr



10.59 Uhr: Keimzahl 15, 22 C, 55% r. F.

11.20 Uhr: Keimzahl 15, 22 C, 55% r. F.

With over 700 units in service our specially developed "WEISS OP system" guarantees low germ counts in the critical operating area, as also confirmed through independent tests by European Hygiene Research Institutes.

### The main features of the system are:

- Steady downward flow through patented "WEISS OP ceiling" with supporting jet streams.
- Modular design ensures suitability for all types of operating theatres.
- Compact air handling units.
- Low noise, low energy consumption and easy maintenance.
- Fast and easy installation.



11.53 Uhr: Keimzahl 15, 22 C, 55% r. F.

12.05 Uhr: Keimzahl

Further detailed information available from



**WEISS TECHNIK LTD**  
ENVIRONMENT - CLIMATE - TESTING

29 MARKET PLACE, KINGSTON UPON THAMES, SURREY KT1 1JH

Telephone: 01-546 1114 Telex: 929512 Schunk G



# PROCEDURES IN PRACTICE

An illustrated step-by-step guide for doctors making their first attempts at the procedures commonly used in hospital practice. The articles explain the techniques in detail and give indications and contraindications for a range of tasks from setting up a drip to aspirating bone marrow.

The articles have been collected into book form in the same format as they appeared in the BMJ.


Price: Inland £4.00;  
Overseas US\$19.00\*  
(Inland £3.50;  
Overseas US\$17.50\* for  
BMA members)

*\*including air mail postage*

**Order your copy now**  
From: The Publisher,  
British Medical Journal,  
BMA House,  
Tavistock Square,  
London WC1H 9JR  
*or any leading bookseller*

## PROCEDURES IN PRACTICE

ARTICLES FROM THE BRITISH MEDICAL JOURNAL



# Nizoral

ketoconazole

## Oral therapy for all common fungal infections

Vaginal candidosis:	In all dermatological and in systemic fungal infections:
2 tablets once daily (with food) for 5 days	1 tablet daily (with food) until complete symptomatic and mycological cure is obtained

Not all indications are as yet approved in all countries.

#### PRESCRIBING INFORMATION

**Presentation:** white, flat, half scored uncoated tablets marked "Janssen" on one side and k 200 on the reverse. Each tablet contains 200 mg ketoconazole. **Uses:** Nizoral is an orally active antimycotic for the treatment in adults of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and G.I. tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children: systemic mycoses and severe local infections where previous topical treatment has failed. **Side-effects, precautions, contra-indications:** contra-indicated in pregnancy. For maximal absorption, Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H<sub>2</sub> blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole. These changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped.



Janssen Pharmaceutica  
B-2340 Beerse, Belgium

**Transderm-Nitro**

glyceryl trinitrate Average absorption rate: 5mg in 24 hours

**New system**

## 24 hour control of angina pectoris through the skin



**Prescribing information** **Presentation** Transderm-Nitro is a transdermal drug delivery system, comprising a self-adhesive, pink-coloured patch, containing a drug reservoir of glyceryl trinitrate BP. The Transderm-Nitro patch has a contact surface measuring 10cm<sup>2</sup>, and a glyceryl trinitrate content of 25mg. **Indication** Prophylactic treatment of attacks of angina pectoris, as monotherapy or in combination with other anti-anginal agents. **Mode of action** Transderm-Nitro is a novel drug delivery system designed to achieve a prolonged and constant release of glyceryl trinitrate. Glyceryl trinitrate acts by venous and arterial vasodilatation and redistribution of myocardial blood flow. Following the application of Transderm-Nitro the plasma level of glyceryl trinitrate reaches a constant plateau within two hours, which is maintained for at least 24 hours. During the first hour after removal of the patch the plasma level falls rapidly. **Dosage and administration** One patch is to be applied every 24 hours. The average total amount of glyceryl trinitrate absorbed per patch in 24 hours is 5mg. It is recommended that the patch is applied to the lateral chest wall. The patch should be removed after 24 hours, and the replacement patch applied to a new area of skin. Allow several days to elapse before applying a fresh patch to the same area of skin. If acute attacks of angina pectoris occur, rapid acting nitrate preparations may be required. Efficacy and tolerability beyond 28 days' therapy have yet to be established. **Side-effects** Headache may occur and usually regresses after a few days. Reflex tachycardia can be controlled by concomitant treatment with a beta-blocker. Postural hypotension, nausea and dizziness occur rarely. Allergic skin reactions, a local mild itching or burning sensation may occasionally occur. Upon removal of the patch, any slight reddening of the skin will usually disappear in a few hours. **Precautions** In recent myocardial infarction or acute heart failure, Transderm-Nitro should be employed only under careful clinical surveillance. As with all anti-anginal nitrate preparations, withdrawal of treatment should be gradual, by replacement with decreasing doses of long-acting oral nitrates. **Contra-indications** Transderm-Nitro should not be prescribed to patients hypersensitive to nitrates, or in severe hypotension. Marked anaemia, increased intraocular pressure or intracranial pressure. **Pregnancy** As with all drugs, Transderm-Nitro should not be prescribed during pregnancy, particularly during the first trimester, unless there are compelling reasons for doing so. **Treatment of overdosage** High doses of glyceryl trinitrate are known to cause pronounced systemic side-effects, e.g. a marked fall in blood pressure or collapse. However, with Transderm-Nitro, the rate controlling membrane will reduce the likelihood of overdosage occurring. In contrast to long-acting oral nitrate preparations, the effect of Transderm-Nitro can be rapidly terminated simply by removing the system. Any fall in blood pressure or signs of collapse that may occur, may be managed by resuscitative measures. **Further information** Transderm-Nitro gives a controlled release of glyceryl trinitrate over at least 24 hours and thereby avoids high peaks of blood levels, minimising the incidence of side-effects. Although glyceryl trinitrate is volatile, resulting, in the case of most products, in loss of the drug after relatively short storage, the design of the Transderm-Nitro patch ensures that the dosage to the patient is maintained even after 2 years' storage. **Packs and price** Boxes of 30 patches. PL0001/0094. Basic NHS price £19.33 \* denotes registered trademark. Full prescribing information is available on request from Geigy Pharmaceuticals, Horsham, West Sussex.

**Geigy**